Accelerating Life- Changing Medicines

We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.

Recent News

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program...

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transf...

Icon 1 / 3 Icon
Acelyrin Test Tube Icon

Our Science

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.

Learn More
Acelyrin Team Icon

Meet Our Leadership

We are led by a team of veteran biopharma executives who bring exceptional track records of developing and commercializing transformative therapies.

Learn More

Courageous Caring

Guided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.


Participants Dosed with Izokibep


Dedicated Professionals

$ M+

Growth financing committed

Clinical-stage programs

We Care as Scientists, and We Care as People
Who We Are

We Care as Scientists, and We Care as People

We have the right blend of scientific, medical, operational and corporate experience to identify, develop and commercialize treatments with the potential to dramatically transform patients’ lives.
Our Story Arrow purple
Our Work

Accelerating Transformative Therapies

We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.

Shao-Lee Lin, MD, PhD
“We are leveraging the power of our team to build a better and brighter future for patients in need.”
Shao-Lee Lin, MD, PhD | Founder and Chief Executive Officer

Join a team that Courageously Cares

ACELYRIN is building a biopharma company with a corporate culture of Courageous Caring - placing patients first and embracing the concept that all of us together are better than any one of us alone. We strive to address the most basic human needs: to live a productive life free from disease.
Learn More Arrow purple
Join a team that Courageously Cares

In the Press


Biotech Startup Buys Drugmaker ValenzaBio in Stock Deal

ACELYRIN, backed with more than $550 million in venture capital, adds to drug pipeline

Read Article Arrow purple

Acelyrin scores series C that brings total raised in less than a year past $500M

Any biotech that can rake in half a billion dollars from investors in 12 months is clearly doing something right.

Read Article Arrow purple

Izokibep Treatment Improves Pain, Function in Patients with Active PsA

Unique IL-17A inhibitor demonstrated notable dose-dependent improvements in sleep, pain and function in patients with psoriatic arthritis.

Read Article Arrow purple
News Center

The Latest Company
Announcements and Resources